Trial Profile
A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase II Study to Assess The Efficacy of AZD9056 (single oral 400 mg dose) when Administered for 4 Weeks in Patients with Moderate to Severe COPD
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Aug 2019
Price :
$35
*
At a glance
- Drugs AZD 9056 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 05 Aug 2019 Status changed from recruiting to completed.
- 18 May 2011 This trial is recruiting in Great Britain and has completed in Hungary and the Sweden.
- 12 May 2011 New trial record